Skip to main content
SpringerLink
Log in

Novel Opportunities for Therapeutic Targeting in Systemic Autoimmune Diseases

  • Protocol
Book cover Target Discovery and Validation Reviews and Protocols

Part of the book series: Methods in Molecular Biology™ ((MIMB,volume 361))

  • 1249 Accesses

Abstract

Systemic autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis, continue to cause significant morbidity in affected persons. In the past few years, significant progress was made in understanding their pathogenesis and the underlying molecular mechanisms. As a result, a number of new exciting therapeutic options have become available, and novel therapeutic targets have emerged, including B-cell depletion therapies, B cell-activating factor of tumor necrosis factor family (BAFF) antagonists, and FcγRIIB receptor antagonists. Also promising is the current interest centered on the development of inhibition of signal transduction pathways, such as pharmacological inhibitors that act at various levels of signal transduction pathways.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kappler, J. W., Roehm, N., and Marrack, P. (1987) T cell tolerance by clonal elimination in the thymus. Cell 49, 273–280.

    Article  CAS  PubMed  Google Scholar 

  2. Kappler, J. W., Staerz, U., White, J., and Marrack, P. C. (1988) Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex. Nature 332, 35–40.

    Article  CAS  PubMed  Google Scholar 

  3. Nemazee, D. and Buerki, K. (1989) Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras. Proc. Natl. Acad. Sci. USA 86, 8039–8043.

    Article  CAS  PubMed  Google Scholar 

  4. Nossal, G. J. and Pike, B. L. (1980) Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc. Natl. Acad. Sci. USA 77, 1602–1606.

    Article  CAS  PubMed  Google Scholar 

  5. Tiegs, S. L., Russell, D. M., and Nemazee, D. (1993) Receptor editing in self-reactive bone marrow B cells. J. Exp. Med. 177, 1009–1020.

    Article  CAS  PubMed  Google Scholar 

  6. Radic, M. Z., Erikson, J., Litwin, S., and Weigert, M. (1993) B lymphocytes may escape tolerance by revising their antigen receptors. J. Exp. Med. 177, 1165–1173.

    Article  CAS  PubMed  Google Scholar 

  7. Radic, M. Z. and Zouali, M. (1996) Receptor editing, immune diversification, and self-tolerance. Immunity 5, 505–511.

    Article  CAS  PubMed  Google Scholar 

  8. Bouneaud, C., Kourilsky, P., and Bousso, P. (2000) Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13, 829–840.

    Article  CAS  PubMed  Google Scholar 

  9. Yan, J. and Mamula, M. J. (2002) Autoreactive T cells revealed in the normal repertoire: escape from negative selection and peripheral tolerance. J. Immunol. 168, 3188–3194.

    CAS  PubMed  Google Scholar 

  10. Zouali, M. (2005) Taming lupus. Sci. Am. 292, 70–77.

    Article  Google Scholar 

  11. Choy, E. H. and Panayi, G. S. (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907–916.

    Article  CAS  PubMed  Google Scholar 

  12. Viau, M. and Zouali, M. (2005) B-lymphocytes, innate immunity, and autoimmunity. Clin. Immunol. 114, 17–26.

    Article  CAS  PubMed  Google Scholar 

  13. Uchida, J., Hamaguchi, Y., Oliver, J. A., et al. (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659–1669.

    Article  CAS  PubMed  Google Scholar 

  14. Goldblatt, F. and Isenberg, D. A. (2005). New therapies for rheumatoid arthritis. Clin. Exp. Immunol. 140, 195–204.

    Article  CAS  PubMed  Google Scholar 

  15. Leandro, M. J., Edwards, J. C., and Cambridge, G. (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. 61, 883–888.

    Article  CAS  PubMed  Google Scholar 

  16. Edwards, J. C., Szczepanski, L., Szechinski, J., et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572–2581.

    Article  CAS  PubMed  Google Scholar 

  17. Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R., and Isenberg, D. A. (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673–2677.

    Article  PubMed  Google Scholar 

  18. Tokunaga, M., Fujii, K., Saito, K., et al. (2005) Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44, 176–182.

    Article  CAS  Google Scholar 

  19. Zouali, M. (2002) B cell diversity and longevity in systemic autoimmunity. Mol. Immunol. 38, 895–901.

    Article  CAS  PubMed  Google Scholar 

  20. Ng, L. G., Mackay, C. R., and Mackay, F. (2005) The BAFF/APRIL system: life beyond B lymphocytes. Mol. Immunol. 42, 763–772.

    Article  CAS  PubMed  Google Scholar 

  21. Gross, J. A., Johnston, J., Mudri, S., et al. (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995–999.

    Article  CAS  PubMed  Google Scholar 

  22. Yan, M., Brady, J. R., Chan, B., et al. (2001) Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol. 11, 1547–1552.

    Article  CAS  PubMed  Google Scholar 

  23. Cheema, G. S., Roschke, V., Hilbert, D. M., and Stohl, W. (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44, 1313–1319.

    Article  CAS  PubMed  Google Scholar 

  24. Stohl, W., Metyas, S., Tan, S. M., et al. (2003) B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 48, 3475–3486.

    Article  PubMed  Google Scholar 

  25. Bolland, S. and Ravetch, J. V. (2000) Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13, 277–285.

    Article  CAS  PubMed  Google Scholar 

  26. McGaha, T. L., Sorrentino, B., and Ravetch, J. V. (2005) Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307, 590–593.

    Article  CAS  PubMed  Google Scholar 

  27. Zouali, M. and Sarmay, G. (2004) B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment. Arthritis Rheum. 50, 2730–2741.

    Article  CAS  PubMed  Google Scholar 

  28. Watanabe, H., Garnier, G., Circolo, A., et al. (2000) Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J. Immunol. 164, 786–794.

    CAS  PubMed  Google Scholar 

  29. Holers, V. M. (2003) The complement system as a therapeutic target in autoimmunity. Clin. Immunol. 107, 140–151.

    Article  CAS  PubMed  Google Scholar 

  30. Neumann, E., Barnum, S. R., Tarner, I. H., et al. (2002) Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 46, 934–945.

    Article  CAS  PubMed  Google Scholar 

  31. Steinman, R. M. and Nussenzweig, M. C. (2002) Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99, 351–358.

    Article  CAS  PubMed  Google Scholar 

  32. Blanco, P., Palucka, A. K., Gill, M., Pascual, V., and Banchereau, J. (2001) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294, 1540–1543.

    Article  CAS  PubMed  Google Scholar 

  33. Pascual, V., Banchereau, J., and Palucka, A. K. (2003) The central role of dendritic cells and interferon-alpha in SLE. Curr. Opin. Rheumatol. 15, 548–556.

    Article  CAS  PubMed  Google Scholar 

  34. Kalkner, K. M., Ronnblom, L., Karlsson Parra, A. K., Bengtsson, M., Olsson, Y., and Oberg, K. (1998) Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. Qjm 91, 393–399.

    Google Scholar 

  35. Ronnblom, L. E., Alm, G. V., and Oberg, K. (1991) Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol. 30, 537–540.

    Article  CAS  PubMed  Google Scholar 

  36. Ronnblom, L. and Alm, G. V. (2001) A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J. Exp. Med. 194, F59–F63.

    Article  CAS  PubMed  Google Scholar 

  37. Baechler, E. C., Gregersen, P. K., and Behrens, T. W. (2004) The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 16, 801–807.

    Article  CAS  PubMed  Google Scholar 

  38. Taylor, P. C., Peters, A. M., Paleolog, E., et al. (2000) Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 43, 38–47.

    Article  CAS  PubMed  Google Scholar 

  39. Voulgari, P. V., Alamanos, Y., Nikas, S. N., Bougias, D. V., Temekonidis, T. I., and Drosos, A. A. (2005) Infliximab therapy in established rheumatoid arthritis: an observational study. Am. J. Med. 118, 515–520.

    Article  CAS  PubMed  Google Scholar 

  40. Emery, P. (2005) Adalimumab therapy: clinical findings and implications for integration into clinical guidelines for rheumatoid arthritis. Drugs Today (Barc) 41, 155–163.

    Article  CAS  Google Scholar 

  41. Sokol, M. C. (2005) Effective coverage and reim bursement strate etanercept and infliximab in the treatment of rheumatoid arthritis. Manag. Care Interface 18, 32–37.

    PubMed  Google Scholar 

  42. Bezerra, M. C., Carvalho, J. F., Prokopowitsch, A. S., and Pereira, R. M. (2005) RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz. J. Med. Biol. Res. 38, 161–170.

    Article  CAS  PubMed  Google Scholar 

  43. Boyle, W. J., Simonet, W. S., and Lacey, D. L. (2003) Osteoclast differentiation and activation. Nature 423, 337–342.

    Article  CAS  PubMed  Google Scholar 

  44. Yun, T. J., Tallquist, M. D., Aicher, A., et al. (2001) Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J. Immunol. 166, 1482–1491.

    CAS  PubMed  Google Scholar 

  45. Kong, Y. Y., Yoshida, H., Sarosi, I., et al. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315–323.

    Article  CAS  PubMed  Google Scholar 

  46. Cheng, G. and Schoenberger, S. P. (2002) CD40 signaling and autoimmunity. Curr. Dir. Autoimmun. 5, 51–61.

    Article  CAS  PubMed  Google Scholar 

  47. Datta, S. K. and Kalled, S. L. (1997) CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum. 40, 1735–1745.

    Article  CAS  PubMed  Google Scholar 

  48. Crow, M. K. and Kirou, K. A. (2001) Regulation of CD40 ligand expression in systemic lupus erythematosus. Curr. Opin. Rheumatol. 13, 361–369.

    Article  CAS  PubMed  Google Scholar 

  49. Toubi, E. and Shoenfeld, Y. (2004) The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 37, 457–464.

    Article  CAS  PubMed  Google Scholar 

  50. Grammer, A. C., Slota, R., Fischer, R., et al. (2003) Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154–CD40 interactions. J. Clin. Invest. 112, 1506–1520.

    CAS  PubMed  Google Scholar 

  51. Morel, J. and Berenbaum, F. (2004) Signal transduction pathways: new targets for treating rheumatoid arthritis. Joint Bone Spine 71, 503–510.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inserm U606, Paris, France

    Meryem Ouarzane & Moncef Zouali

  2. University of Paris 7, Paris, France

    Meryem Ouarzane & Moncef Zouali

  3. Centre Viggo Petersen, l’Hôspital Lariboisière, Paris, France

    Meryem Ouarzane & Moncef Zouali

Authors
  1. Meryem Ouarzane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Moncef Zouali
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway

    Mouldy Sioud

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc.

About this protocol

Cite this protocol

Ouarzane, M., Zouali, M. (2007). Novel Opportunities for Therapeutic Targeting in Systemic Autoimmune Diseases. In: Sioud, M. (eds) Target Discovery and Validation Reviews and Protocols. Methods in Molecular Biology™, vol 361. Humana Press. https://doi.org/10.1385/1-59745-208-4:285

Download citation

  • DOI: https://doi.org/10.1385/1-59745-208-4:285

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-890-4

  • Online ISBN: 978-1-59745-208-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation